Two biotechs fail to beat or match Re­gen­eron's Eylea in key tri­als

Opthea and Uni­ty Biotech­nol­o­gy, which are both de­vel­op­ing new drugs for eye dis­eases, were un­able to beat or match afliber­cept, the stan­dard-of-care treat­ment that Re­gen­eron …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER